专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5169930A Fibronectin receptor 失效
标题翻译：纤维蛋白受体
公开(公告)号：US5169930A
公开(公告)日：1992-12-08
申请号：US461349
申请日：1990-01-05
申请人： Erkki I. Ruoslahti , Guido Tarone , Filippo G. Giancotti , Bruce E. Vogel
发明人： Erkki I. Ruoslahti , Guido Tarone , Filippo G. Giancotti , Bruce E. Vogel
IPC分类号： C07K14/435 , A61K38/00 , C07K1/16 , C07K1/22 , C07K14/705 , C07K16/00 , C07K16/28 , C12N15/02 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/53
CPC分类号： C07K14/7055 , A61K38/00
摘要： The present invention provides a substantially pure integrin-type receptor characterized in that it consists of an .alpha..sub.v and a .beta..sub.1 subunit. The .alpha..sub.v .beta..sub.1 integrin binds to fibronectin and GRGDSPK but does not bind to vitronectin. The .alpha..sub.v .beta..sub.1 integrin can be used to determine the presence of a .alpha..sub.v .beta..sub.1 ligand and to develop adhesion peptides specific for the various integrins. The presence of the .alpha..sub.v .beta..sub.1 integrin can be used to assess ability of cells to adhere to fibronectin.
摘要翻译：本发明提供了基本上纯的整联蛋白型受体，其特征在于其由αv和β1亚单位组成。 αvβ1整联蛋白与纤连蛋白和GRGDSPK结合，但不结合玻连蛋白。 αvβ1整联蛋白可用于确定αvβ1配体的存在并开发针对各种整合素特异的粘附肽。 αvβ1整联蛋白的存在可用于评估细胞粘附纤连蛋白的能力。

2. 发明授权

US5591592A Method for detection of fibronectin receptor ligands 失效
标题翻译：纤连蛋白受体配体检测方法
公开(公告)号：US5591592A
公开(公告)日：1997-01-07
申请号：US279279
申请日：1994-07-22
申请人： Erkki I. Ruoslahti , Guido Tarone , Filippo G. Giancotti , Bruce E. Vogel
发明人： Erkki I. Ruoslahti , Guido Tarone , Filippo G. Giancotti , Bruce E. Vogel
IPC分类号： C07K14/435 , A61K38/00 , C07K1/16 , C07K1/22 , C07K14/705 , C07K16/00 , C07K16/28 , C12N15/02 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/566 , G01N33/539 , G01N33/543
CPC分类号： C07K14/7055 , A61K38/00
摘要： The present invention provides a substantially pure integrin characterized in that it consists of an .alpha..sub.v and a .beta..sub.1 subunit. The receptor binds to fibronectin and GRGDSPK but does not bind to vitronectin. The .alpha..sub.v .beta..sub.1 receptor can be used to determine the presence of ligands for the receptor.
摘要翻译：本发明提供了基本上纯的整联蛋白，其特征在于其由αv和β1亚基组成。受体结合纤连蛋白和GRGDSPK，但不结合玻连蛋白。 αvβ1受体可用于确定受体配体的存在。

3. 发明申请

US20080317752A1 Inhibition of Tumorigenesis by Inhibition of a6b4 Integrin 审中-公开
标题翻译：抑制a6b4整合素抑制肿瘤发生
公开(公告)号：US20080317752A1
公开(公告)日：2008-12-25
申请号：US10596364
申请日：2006-04-18
申请人： Filippo G. Giancotti
发明人： Filippo G. Giancotti
IPC分类号： A61K39/395 , A61K31/7088 , A61P35/00
CPC分类号： C07K16/2839
摘要： Inhibitors of a6b4 integrin that target beta 4 are used as therapeutic agents to inhibit tumorigensis in individuals, including humans, of tumors that express a6b4 integrin. The therapeutic agent may be an antibody or a small molecule, for example a laminin-5 analog, which binds to a6b4 integrin and inhibits its normal function. The therapeutic agent may also be a chemical species that interferes with the production of beta 4, including for example an antisense or RNAi species. The therapeutic agent is administered to the tissue or patient in a therapeutically effective amount. The therapeutic agent may be used as a single agent or in combination with other therapies, especially those directed toward suppressing the activity of RPTKs known to cooperate with a6b4, including but not limited to ErbB2, EGF-R, Met, and Ron.
摘要翻译：靶向β4的a6b4整联蛋白的抑制剂用作治疗剂以抑制表达一种6b4整联蛋白的肿瘤的个体（包括人）的肿瘤发生。治疗剂可以是抗体或小分子，例如层粘连蛋白-5类似物，其结合a6b4整联蛋白并抑制其正常功能。治疗剂也可以是干扰β4产生的化学物质，包括例如反义或RNAi物种。治疗剂以治疗有效量施用于组织或患者。治疗剂可以用作单一药剂或与其它治疗剂组合使用，特别是那些旨在抑制已知与db4（包括但不限于ErbB2，EGF-R，Met和Ron）配合的RPTK的活性的治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式